Revvity had its Relative Strength (RS) Rating upgraded from 69 to 72 Friday — a welcome improvement, but still shy of the 80 or better score you prefer to see.
IBD's proprietary rating tracks price movement with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history reveals that the best stocks often have an RS Rating north of 80 in the early stages of their moves. See if Revvity can continue to rebound and clear that threshold.
How To Invest In Stocks In Both Bull And Bear Markets
Revvity is building a consolidation with a 129.50 buy point. See if the stock can clear the breakout price in heavy volume.
In terms of top and bottom line numbers, the company has posted rising EPS growth in each of the last three reports. Revenue growth has also risen over the same time frame. The company is expected to release its next quarterly numbers on or around Jan. 29.
Revvity holds the No. 14 rank among its peers in the Medical-Research Equipment/Services industry group. Veracyte, Natera and Bio-Techne are among the top 5 highly rated stocks within the group.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
